Table III.
Pathways of potential target genes of miR-183-5p in bladder cancer.
| Pathway | No. of genes in the dataset | Percentage of genes | Fold enrichment | P-value (Hypergeometric test) | Gene |
|---|---|---|---|---|---|
| MF: Cytoskeletal protein binding | 5 | 5.682 | 5.021 | 0.003 | TPM1; KLHL4; LMOD1; TMOD1; MAPRE2 |
| MF: Protein threonine/tyrosine kinase activity | 2 | 2.273 | 15.679 | 0.007 | MAP3K8; TRIB1 |
| MF: Phosphoric diester hydrolase activity | 2 | 2.273 | 15.139 | 0.008 | PDE1A; PDE4D |
| MF: B cell receptor activity | 1 | 1.136 | 44.049 | 0.023 | CD79B |
| MF: Receptor activity | 5 | 5.682 | 3.032 | 0.025 | CDON; GFRA1; UNC5C; CNTNAP1; SORCS2 |
| BP: Calcium-mediated signaling | 2 | 2.273 | 48.744 | 0.001 | PLCB4; TRPM3 |
| BP: Apoptosis | 5 | 5.682 | 4.976 | 0.003 | CSRNP1; CSRNP3; BAG3; SNRK; DLC1 |
| BP: Cell communication | 27 | 30.682 | 1.589 | 0.007 | STC1; CDC42EP3; GPR3; PLCB4; SPRY2; EPHA2; MAP3K8; RHOB; AR; CDON; CXCL12; DGKB; GRIN2A; PDE1A; PDE4D; TNS1; UNC5C; CNTNAP1; GPR155; IGF1; ROCK1; SORCS2; FGF2; INHBB; TRIB1; MYOZ2; RUNDC3B |
| BP: Signal transduction | 28 | 31.818 | 1.556 | 0.008 | STC1; CDC42EP3; GPR3; PLCB4; SPRY2; EPHA2; MAP3K8; RHOB; AR; CDON; CXCL12; DGKB; GFRA1; GRIN2A; PDE1A; PDE4D; TNS1; UNC5C; CNTNAP1; GPR155; IGF1; ROCK1; SORCS2; FGF2; INHBB; TRIB1; MYOZ2; RUNDC3B |
| BP: Anti-apoptosis | 2 | 2.273 | 13.720 | 0.009 | NAMPT; IGF1 |
| CC: Sarcomere | 3 | 3.409 | 43.816 | <0.001 | TPM1; SYNE1; MYOZ2 |
| CC: Cytoplasm | 43 | 48.864 | 1.653 | <0.001 | STC1; ATP2B4; CDC42EP3; SPRY2; THRA; AKAP12; ATP1A2; CLIC4; FBXO30; MAP3K8; TLE4; TPM1; AR; DGKB; DGKG; GFRA1; GRIN2A; KLHL4; LMOD1; MITF; NAMPT; PDE1A; PDE4D; PPP1R12A; SBDS; SETBP1; TMOD1; BAG3; HAND1; IGF1; MAPRE2; ROCK1; SYNE1; TRPM3; ESR1; EYA1; TRIB1; WWTR1; MYOZ2; CD79B; GSTM5; RPS6KA5; DLC1 |
| CC: Plasma membrane | 27 | 30.682 | 1.696 | 0.003 | ATP2B4; GPR3; SPRY2; AKAP12; ATP1A2; CLIC4; EPHA2; RHOB; AR; CAV1; CDON; DGKB; DGKG; GFRA1; GRIN2A; PPP1R12A; TNS1; UNC5C; CNTNAP1; GPR155; SORCS2; TRPM3; ESR1; FGF2; TES; SLC24A4; CD79B |
| CC: Nucleus | 39 | 44.318 | 1.458 | 0.004 | STC1; ZFPM2; ATP2B4; PLCB4; THRA; TRPS1; AKAP12; ATP1A2; CLIC4; CSRNP1; CSRNP3; TLE4; TPM1; ZEB2; AR; BNC2; CREM; GFRA1; MITF; NAMPT; PDE4D; PPP1R12A; SBDS; SETBP1; TMOD1; CNTNAP1; HAND1; MAPRE2; SYNE1; TRPM3; ESR1; EYA1; FGF2; TRIB1; KLF12; WWTR1; SNRK; RPS6KA5; DLC1 |
| CC: Caveola | 2 | 2.273 | 18.292 | 0.005 | CAV1; DLC1 |
| Biological pathway: Epithelial-to-mesenchymal transition | 13 | 14.773 | 15.365 | <0.001 | ZFPM2; AKAP12; CLIC4; ZEB2; BNC2; CAV1; CXCL12; SOBP; TNS1; IGF1; SYNE1; PTX3; WWTR1 |
| Biological pathway: Stabilization and expansion of the E-cadherin adherens junction | 8 | 9.091 | 6.364 | <0.001 | SPRY2; EPHA2; TLE4; AR; GFRA1; MITF; IGF1; ROCK1 |
| Biological pathway: E-cadherin signaling in the nascent adherens junction | 8 | 9.091 | 6.364 | <0.001 | SPRY2; EPHA2; TLE4; AR; GFRA1; MITF; IGF1; ROCK1 |
| Biological pathway: E-cadherin signaling events | 8 | 9.091 | 6.250 | <0.001 | SPRY2; EPHA2; TLE4; AR; GFRA1; MITF; IGF1; ROCK1 |
| Biological pathway: Syndecan-4-mediated signaling events | 7 | 7.955 | 7.328 | <0.001 | TLE4; AR; CAV1; CXCL12; MITF; ROCK1; FGF2 |